{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:15:05Z","timestamp":1788243305934,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTRQQR-2021\\100006"],"award-info":[{"award-number":["CTRQQR-2021\\100006"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTRQQR-2021\\100006"],"award-info":[{"award-number":["CTRQQR-2021\\100006"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pathology is central to many biologically driven cancer clinical trials. Biomarker-led and translational studies depend on robust tissue pathways, cellular and molecular assays, pathology-derived endpoints, and clinically meaningful interpretation of discovery science. Where trials depend on tumour material, biomarker-defined eligibility or mechanism-focused endpoints, pathology expertise should be embedded early, before protocols, budgets, and assays are fixed. Early pathology input strengthens feasibility, specimen governance, assay selection, quality assurance, and the long-term value of collected samples. In the UK, the Clinical Trials Pathology Advisory Group, now within the new Pathological Society of Great Britain and Ireland Clinical Trials Pathology subcommittee, provides a practical route for pre-submission specialist review. This Perspective argues that pathology is core infrastructure for biologically rich trials, linking discovery science to clinical translation.<\/jats:p>","DOI":"10.1038\/s41416-026-03605-9","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:25Z","timestamp":1788240925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why early pathology input matters in biologically rich cancer trials"],"prefix":"10.1038","author":[{"given":"Manas","family":"Dave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-2501","authenticated-orcid":false,"given":"Maggie Chon U.","family":"Cheang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9634-9738","authenticated-orcid":false,"given":"Tomoko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-1259","authenticated-orcid":false,"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna","family":"Shamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-2786","authenticated-orcid":false,"given":"Timothy J.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"3605_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/his.14099","volume":"76","author":"E Provenzano","year":"2020","unstructured":"Provenzano E, Driskell OJ, O\u2019Connor DJ, Rodriguez-Justo M, McDermott J, Wong N, et al. The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. Histopathology. 2020;76:942\u20139.","journal-title":"Histopathology"},{"key":"3605_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00428-024-04005-1","volume":"486","author":"X Matias-Guiu","year":"2025","unstructured":"Matias-Guiu X, Raspollini MR, Kulka J, Ryska A, Al Dieri R, Schirmacher P. The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology. Virchows Arch. 2025;486:207\u201314.","journal-title":"Virchows Arch"},{"key":"3605_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/path.4261","volume":"232","author":"ID Nagtegaal","year":"2014","unstructured":"Nagtegaal ID, West NP, van Krieken JH, Quirke P. Pathology is a necessary and informative tool in oncology clinical trials. J Pathol. 2014;232:185\u20139.","journal-title":"J Pathol"},{"key":"3605_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cjp2.199","volume":"7","author":"SJ Lim","year":"2021","unstructured":"Lim SJ, Gurusamy K, O\u2019Connor D, Shaaban AM, Brierley D, Lewis I, et al. Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation. J Pathol Clin Res. 2021;7:191\u2013202.","journal-title":"J Pathol Clin Res"},{"key":"3605_CR5","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S1470-2045(21)00344-2","volume":"22","author":"TJ Kendall","year":"2021","unstructured":"Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O\u2019Connor DJ, Shaaban AM, et al. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22:e435\u2013e45.","journal-title":"Lancet Oncol"},{"key":"3605_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/cjp2.274","volume":"8","author":"P Robinson","year":"2022","unstructured":"Robinson P, Bacon CM, Lim SJ, Shaaban AM, Brierley D, Lewis I, et al. Assessment of clinical trial protocols for pathology content using the SPIRIT-Path guidelines highlights areas for improvement. J Pathol Clin Res. 2022;8:411\u201321.","journal-title":"J Pathol Clin Res"},{"key":"3605_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158:200\u20137.","journal-title":"Annals of Internal Medicine"},{"key":"3605_CR8","unstructured":"Robinson P Update and remapping of SPIRIT-Path extension 2026: protocol [Online]. United States of America: Center for Open Science; 2026 [Available from: https:\/\/osf.io\/96yjp\/overview."},{"key":"3605_CR9","doi-asserted-by":"publisher","first-page":"e081477","DOI":"10.1136\/bmj-2024-081477","volume":"389","author":"A-W Chan","year":"2025","unstructured":"Chan A-W, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081477.","journal-title":"BMJ"},{"key":"3605_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, Andr\u00e9 F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28:658\u201365.","journal-title":"Nat Med"},{"key":"3605_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.5858\/arpa.2013-0691-RA","volume":"138","author":"BP Bass","year":"2014","unstructured":"Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med. 2014;138:1520\u201330.","journal-title":"Arch Pathol Lab Med"},{"key":"3605_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","volume":"18","author":"SM Lewis","year":"2021","unstructured":"Lewis SM, Asselin-Labat M-L, Nguyen Q, Berthelet J, Tan X, Wimmer VC, et al. Spatial omics and multiplexed imaging to explore cancer biology. Nature Methods. 2021;18:997\u20131012.","journal-title":"Nature Methods"},{"key":"3605_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/jclinpath-2015-203097","volume":"69","author":"SD Richman","year":"2016","unstructured":"Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, et al. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. J Clin Pathol. 2016;69:35\u201341.","journal-title":"J Clin Pathol"},{"key":"3605_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jclinpath-2022-208233","volume":"76","author":"SD Richman","year":"2023","unstructured":"Richman SD, Hemmings G, Roberts H, Gallop N, Dodds R, Wilkinson L, et al. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. J Clin Pathol. 2023;76:548\u201354.","journal-title":"J Clin Pathol"},{"key":"3605_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","volume":"583","author":"G Middleton","year":"2020","unstructured":"Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020;583:807\u201312.","journal-title":"Nature"},{"key":"3605_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","volume":"21","author":"NC Turner","year":"2020","unstructured":"Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21:1296\u2013308.","journal-title":"Lancet Oncol"},{"key":"3605_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cjp2.124","volume":"5","author":"G Rees","year":"2019","unstructured":"Rees G, Salto-Tellez M, Lee JL, Oien K, Verrill C, Freeman A, et al. Training and accreditation standards for pathologists undertaking clinical trial work. J Pathol Clin Res. 2019;5:100\u20137.","journal-title":"J Pathol Clin Res"},{"key":"3605_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/cjp2.121","volume":"5","author":"M Robinson","year":"2019","unstructured":"Robinson M, James J, Thomas G, West N, Jones L, Lee J, et al. Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. J Pathol Clin Res. 2019;5:91\u20139.","journal-title":"J Pathol Clin Res"},{"key":"3605_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/modpathol.2017.30","volume":"30","author":"JSJ Thomas","year":"2017","unstructured":"Thomas JSJ, Provenzano E, Hiller L, Dunn J, Blenkinsop C, Grybowicz L, et al. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Mod Pathol. 2017;30:1069\u201377.","journal-title":"Mod Pathol"},{"key":"3605_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cjp2.127","volume":"5","author":"R Pell","year":"2019","unstructured":"Pell R, Oien K, Robinson M, Pitman H, Rajpoot N, Rittscher J, et al. The use of digital pathology and image analysis in clinical trials. J Pathol Clin Res. 2019;5:81\u201390.","journal-title":"J Pathol Clin Res"},{"key":"3605_CR21","unstructured":"UK Trial Managers Network. The Guide to Efficient Trial Management Cancer Supplement United Kingdom: UK Trial Managers Network; 2020 [Available from: https:\/\/www.tmn.ac.uk\/resources\/35-the-guide-to-efficient-trial-management-cancer-supplement."},{"key":"3605_CR22","unstructured":"Royal College of Pathologists. President\u2019s e-newsletter \u2013 March 2017 [Online]. United Kingdom: Royal College of Pathologists; 2017 [Available from: https:\/\/www.rcpath.org\/static\/c756f067-1091-4003-bf0cf44f20a97bf7\/E-newsletter-March-2017.pdf."},{"key":"3605_CR23","unstructured":"National Cancer Research Institute. NCRI Annual Review 2017-2018 [Online]. United Kingdom: NCRI; 2018 [Available from: https:\/\/register-of-charities.charitycommission.gov.uk\/en\/charity-search?p_p_id=uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet&p_p_lifecycle=2&p_p_state=maximized&p_p_mode=view&p_p_resource_id=%2Faccounts-resource&p_p_cacheability=cacheLevelPage&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_objectiveId=A9331463&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_priv_r_p_mvcRenderCommandName=%2Ffull-print&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_priv_r_p_organisationNumber=5055656."},{"key":"3605_CR24","unstructured":"Pathological Society of Great Britain and Ireland. Clinical Trials Sub - committee [Online]. United Kingdom: PathSoc; 2025 [Available from: https:\/\/www.pathsoc.org\/about\/subcommittees\/clinical_trials_sub_-_committee.aspx."},{"key":"3605_CR25","unstructured":"Pathological Society of Great Britain and Ireland. Annual General Meeting [Online]. United Kingdom: PathSoc; 2025 [Available from: https:\/\/www.pathsoc.org\/_userfiles\/pages\/files\/2025_annual_general_meeting_booklet_final.pdf."},{"key":"3605_CR26","unstructured":"Cancer Research UK. Open Lab Initiative [Online]. United Kingdom: CRUK; 2026 [Available from: https:\/\/www.crukcentre.manchester.ac.uk\/engage\/open-lab-initiative\/."},{"key":"3605_CR27","unstructured":"The Association of Medical Research Charities. New UK Collaborative for Cancer Clinical Research launched [Online]. United Kingdom: AMRC; 2025 [Available from: https:\/\/www.amrc.org.uk\/news\/new-uk-collaborative-for-cancer-clinical-research-launched."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03605-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:27Z","timestamp":1788240927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03605-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":27,"alternative-id":["3605"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03605-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CB received honoraria as a speaker from AstraZeneca, Incyte, Servier, and honoraria as a consultant from Incyte, Servier, Boehringer Ingelheim, AstraZeneca, Tahio, Jazz Pharmaceuticals, Molecular Partners, Delcath; received research funds from Avacta, Medannex, Servier, and her spouse is an employee of AstraZeneca. GB received honoraria as a consultant from MSD. MC is the co-inventor of PAM50\/Prosigna, commercially licensed by Veracyte, with royalties paid, and serves as a scientific advisor for AstraZeneca. TJK has served as a consultant or advisory board member for Resolution Therapeutics, Clinnovate Health, HistoIndex, Fibrofind, Kynos Therapeutics, Perspectum, Concept Life Sciences, Servier Laboratories, Taiho Oncology, Roche, and Jazz Pharmaceuticals, and has received speakers\u2019 fees from Servier Laboratories, Jazz Pharmaceuticals, AstraZeneca, HistoIndex, Taiho Oncology, and Incyte Corporation. The other authors do not declare any competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}